Raise closed, search for fresh raises on Seedstage

San Jose, CA

Developing innovative cancer detection technology to improve diagnostics and treatment.

• Mission: Advancing medical technology for the early detection of skin cancer, aiming to improve diagnostic accuracy and treatment processes with the AURA™ device.  
• Innovation: AURA™ uses advanced Raman technology for non-invasive, real-time diagnostics, reducing the need for biopsies and enabling faster, more efficient detection of pre-cancerous and malignant lesions.  
• Market Opportunity: Targeting the growing global cancer diagnostics market, with a focus on skin cancer, which is the most prevalent cancer in the U.S. and continues to affect a significant portion of the population.  
• Regulatory Pathway: Currently undergoing FDA review, with expected clearance in early 2025, and plans to expand market reach through regulatory approvals in Canada, the EU, and Australia.  
• Healthcare Impact: By enhancing early detection capabilities, Vita Imaging aims to significantly improve patient outcomes, potentially saving lives through more effective and timely cancer diagnosis.  
• Growth Strategy: Seeking funds to support regulatory approvals, product development, and market expansion, positioning the company for significant growth in the global cancer diagnostics sector.  

Vita Imaging is a pioneering medical device company focused on developing innovative cancer detection technologies, specifically targeting skin cancer through its lead product, the AURA™ device. This cutting-edge technology aims to provide real-time diagnostics, significantly reducing the need for biopsies and optimizing treatment processes.

With skin cancer being the most prevalent cancer in the U.S., affecting a substantial portion of the population, the company recognizes the urgent need for effective diagnostic tools. The AURA™ device, which has received accolades for its rapid detection capabilities, is currently undergoing FDA review with an expected clearance in early 2025.

In addition to seeking approval in the U.S., Vita Imaging plans to expand its market reach by pursuing regulatory approvals in Canada, the European Union, and Australia. The fundraising initiative aims to support these efforts and facilitate the growth of the company, ultimately contributing to the global cancer diagnostics market, which is projected to experience significant growth in the coming years.

By investing in Vita Imaging, stakeholders can play a role in advancing medical technology that could potentially save lives and improve patient outcomes in the fight against cancer.

Company Info

Vita Imaging, Inc. develops innovative diagnostic systems for the early detection of cancer, focusing on skin cancer.

Vita Imaging, Inc. is a medical technology company focused on the development and commercialization of innovative diagnostic systems for the early detection of cancer, particularly skin cancer. The company has created AURA™, a non-invasive imaging and spectroscopy system that utilizes advanced Raman technology to provide real-time results for cancer screening. AURA™ aims to assist healthcare professionals in the rapid identification of pre-cancerous and malignant lesions, potentially improving patient outcomes through early detection. The company is currently undergoing FDA review for AURA™’s market clearance, with a decision expected in 2025. Vita Imaging collaborates with leading scientists and healthcare providers to enhance its technology and ensure its efficacy in cancer detection, addressing the growing prevalence of skin cancer globally.